guselkumab · Tremfya

Monoclonal antibody

Also known as CNTO 1959

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis (label: moderately to severely active UC who have had an inadequate response, lost response, or were...)

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (10)
JP
  • Moderately to severely active Crohn's disease where existing therapy is inadequatekyodonewsprwire.jp
  • Moderately to severely active ulcerative colitis: IV 200 mg induction, SC 200 mg maintenance; 100 mg syringe maintenance addedkyodonewsprwire.jp
  • Psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis where existing therapy is inadequatetaiho.co.jp
Product first approved 2018
EU
  • Adults with moderately to severely active Crohn's diseasepearceip.law
  • Moderate to severe plaque psoriasis in adults (initial EU authorisation; PsA, UC and Crohn's later)EMA
  • Adults with moderately to severely active ulcerative colitis when other treatments have not worked well enough, have stopped working, or have caused unacceptable side effectsEMA
  • Adults with psoriatic arthritis, alone or with methotrexate, when disease-modifying medicines have not worked well enough or have caused unacceptable side effectsEMA
Product first approved 2017
UK
  • Moderately to severely active ulcerative colitis in adult patients
Product first approved 2024medicines.org.uk
CN
  • Moderate to severe plaque psoriasis in adults (import approval reported 2019-12-30)
Product first approved 2019pharmvestnik.ru
CA
  • Plaque Psoriasis TREMFYA (guselkumab injection) is indicated for: • the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Psoriatic Arthritis TREMFYA (guselkumab injection) is indicated for: • the treatment of adult patients with active psoriatic arthritis. TREMFYA can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate). Crohn’s disease TREMFYA/TREMFYA I.V. (guselkumab injection/guselkumab for injection) is indicated for: • the treatment of adult...
Product first approved 2017Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (31)
Crohn's Disease
NCT07499232 · Janssen Research & Development, LLC
2026-04-21 – 2030-12-11 · Crohn Disease
What this study did
NCT05923073 · Janssen Research & Development, LLC
2024-03-13 – 2028-08-14 · Crohn's Disease
What this study did
NCT05197049 · Janssen Research & Development, LLC
2022-01-19 – 2028-03-27 · Crohn Disease
What this study did
NCT06408935 · Janssen-Cilag Ltd.
2024-04-17 – 2028-03-06 · Crohn's Disease
What this study did
NCT05347095 · Janssen-Cilag Ltd.
2022-09-27 – 2027-03-25 · Fistulizing Crohns Disease, Perianal Crohns Disease
What this study did
NCT05784129 · Janssen Research & Development, LLC
2023-02-21 – 2023-10-10 · Crohn's Disease
What this study did
Psoriasis
NCT05272150 · Janssen Research & Development, LLC
2022-07-13 – 2025-05-30 · Plaque Psoriasis, Scalp Psoriasis
What this study did
NCT06039189 · Janssen Research & Development, LLC
2023-08-24 – 2025-04-14 · Moderate Plaque Psoriasis
What this study did
NCT03818035 · Janssen-Cilag International NV
2019-02-08 – 2025-01-07 · Psoriasis
What this study did
NCT03998683 · Janssen-Cilag Ltd.
2019-09-03 – 2021-11-30 · Psoriasis
What this study did
NCT02325219 · Janssen Pharmaceutical K.K.
2014-12-19 – 2019-02-08 · Psoriasis
What this study did
NCT02951533 · Janssen-Cilag G.m.b.H
2016-12-12 – 2019-02-06 · Psoriasis
What this study did
NCT02343744 · Janssen Pharmaceutical K.K.
2015-01-19 – 2018-11-02 · Pustular Psoriasis
What this study did
NCT03090100 · Janssen Research & Development, LLC
2017-04-27 – 2018-09-20 · Psoriasis
What this study did
Psoriatic Arthritis
NCT06663332 · Janssen Research & Development, LLC
2024-10-29 – 2032-02-25 · Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
What this study did
NCT05669833 · University of Pennsylvania
2023-07-14 – 2027-01 · Psoriatic Arthritis
What this study did
NCT04936308 · Janssen Research & Development, LLC
2021-09-28 – 2026-07-02 · Arthritis, Psoriatic
What this study did
NCT05083182 · Janssen Research & Development, LLC
2022-08-30 – 2026-06-23 · Arthritis, Juvenile
What this study did
NCT03796858 · Janssen Pharmaceutica N.V., Belgium
2019-03-22 – 2020-11-11 · Arthritis, Psoriatic
What this study did
Ulcerative Colitis
NCT06260163 · Janssen Research & Development, LLC
2024-01-19 – 2027-04-28 · Colitis, Ulcerative
What this study did
Other / comorbidity
NCT02641730 · Janssen Pharmaceutical K.K.
2015-12-15 – 2018-07-17 · Palmoplantar Pustulosis
What this study did
Phase 2/3 (3)
Crohn's Disease
Ulcerative Colitis
Other / comorbidity
NCT05535738 · Wei-Che Ko
2022-11-15 – 2027-12-31 · Skin Inflammation, Allergic Contact Dermatitis
What this study did
Phase 2 (17)
Crohn's Disease
NCT05242471 · Janssen Research & Development, LLC
2022-07-22 – 2029-11-05 · Crohn's Disease
What this study did
Psoriasis
NCT03553823 · Novartis Pharmaceuticals
2019-01-14 – 2020-01-28 · Chronic Plaque-type Psoriasis
What this study did
NCT01483599 · Janssen Inc.
2011-11-10 – 2013-08-05 · Psoriasis
What this study did
Psoriatic Arthritis
NCT02319759 · Janssen Research & Development, LLC
2015-03-27 – 2017-01-17 · Psoriatic Arthritis
What this study did
Ulcerative Colitis
NCT05242484 · Janssen Research & Development, LLC
2022-09-19 – 2029-03-27 · Colitis, Ulcerative
What this study did
NCT03662542 · Janssen Research & Development, LLC
2018-11-20 – 2021-11-15 · Colitis, Ulcerative
What this study did
Other / comorbidity
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT06563323 · Oregon Health and Science University
2025-02-01 – 2027-10-05 · Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
What this study did
NCT06651489 · Yale University
2025-03-13 – 2026-12 · Hailey Hailey Disease
What this study did
NCT04683029 · Janssen Pharmaceutical K.K.
2021-02-24 – 2024-07-09 · Scleroderma, Systemic
What this study did
NCT04633447 · Janssen Research & Development, LLC
2020-12-10 – 2024-05-22 · Giant Cell Arteritis
What this study did
NCT03975153 · Oregon Health and Science University
2019-10-03 – 2024-03-22 · Pityriasis Rubra Pilaris
What this study did
NCT04376827 · Janssen Research & Development, LLC
2020-09-15 – 2023-02-01 · Lupus Nephritis
What this study did
NCT04061395 · University Medical Center Groningen
2019-10-01 – 2022-04-01 · Hidradenitis Suppurativa
What this study did
NCT03628924 · Janssen Research & Development, LLC
2018-09-04 – 2020-05-22 · Hidradenitis Suppurativa
What this study did
NCT01845987 · Janssen Pharmaceutical K.K.
2013-06 – 2014-09 · Palmoplantaris Pustulosis
What this study did
Phase 1 (15)
Psoriasis
NCT00925574 · Centocor, Inc.
2009-06-04 – 2010-10-11 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05083078 · Janssen Research & Development, LLC
2021-11-04 – 2022-07-01 · Arthritis, Psoriatic, Healthy
What this study did
Other / comorbidity
NCT04736966 · University of California, San Diego
2021-03-03 – 2024-03-31 · Alcoholic Liver Disease
What this study did
NCT03649971 · Janssen Research & Development, LLC
2018-11-19 – 2022-03-23 · Adenomatous Polyposis Coli
What this study did
NCT04147338 · Janssen Research & Development, LLC
2019-10-30 – 2021-12-07 · Healthy
What this study did
NCT04704843 · Janssen Research & Development, LLC
2021-06-17 – 2021-09-13 · Celiac Disease
What this study did
NCT04617691 · Janssen Research & Development, LLC
2020-11-30 – 2021-07-20 · Healthy
What this study did
NCT04030533 · Janssen Research & Development, LLC
2019-11-29 – 2020-12-31 · Healthy
What this study did
NCT04084665 · Rockefeller University
2020-06-01 – 2020-07-30 · Hidradenitis Suppurativa
What this study did
NCT03536325 · Janssen Pharmaceutical K.K.
2018-05-31 – 2018-10-25 · Healthy
What this study did
NCT02570373 · Janssen Research & Development, LLC
2015-09-25 – 2016-01-12 · Healthy
What this study did
NCT01866007 · Janssen Research & Development, LLC
2013-05-09 – 2013-10-09 · Healthy
What this study did
Phase 4 (17)
Crohn's Disease
NCT07616687 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2026-06-18 – 2029-03-15 · Crohn Disease (CD), Intensification
What this study did
NCT07310095 · Xian-Janssen Pharmaceutical Ltd.
2025-12-30 – 2027-11-15 · Crohn Disease
What this study did
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT05004727 · NYU Langone Health
2022-02-16 – 2028-11-02 · Psoriasis
What this study did
NCT05858632 · University of California, San Francisco
2023-07-01 – 2028-06-30 · Psoriasis of Scalp
What this study did
NCT06398106 · University Hospital, Ghent
2024-12-20 – 2028-03-01 · Psoriasis Vulgaris
What this study did
NCT06974474 · Fondazione Policlinico Universitario Campus Bio-Medico
2024-06-18 – 2027-05-27 · Psoriasis Arthritis
What this study did
NCT04645355 · University of California, San Francisco
2021-03-01 – 2025-04-04 · Psoriasis Guttate, Plaque Psoriasis
What this study did
NCT04340076 · Radboud University Medical Center
2020-08-20 – 2025-01-31 · Psoriasis, Psoriasis Vulgaris
What this study did
NCT04080648 · University Hospital, Ghent
2018-06-27 – 2023-12-31 · Psoriasis Vulgaris
What this study did
NCT04914429 · Janssen Research & Development, LLC
2021-08-25 – 2023-09-26 · Psoriasis
What this study did
NCT05125679 · Janssen-Cilag Ltd.
2021-11-23 – 2023-07-28 · Psoriasis
What this study did
NCT03573323 · Eli Lilly and Company
2018-11-09 – 2020-01-08 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT07141004 · Johnson & Johnson Private Limited
2025-08-12 – 2027-09-11 · Arthritis, Psoriatic
What this study did
NCT07654751 · Janssen Research & Development, LLC
2026-08-07 – 2027-08-31 · Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic
What this study did
NCT04929210 · Janssen Research & Development, LLC
2021-08-30 – 2027-04-13 · Arthritis, Psoriatic
What this study did
Other / comorbidity
NCT06916390 · Universitaire Ziekenhuizen KU Leuven
2026-04-23 – 2029-05-30 · Pouchitis
What this study did
Early phase / not applicable (3)
Psoriasis
NCT07532486 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-07-10 – 2027-07-10 · Psoriasis
What this study did
NCT04394936 · Centre for Human Drug Research, Netherlands
2020-09-01 – 2023-03-27 · Psoriasis Vulgaris
What this study did
Psoriatic Arthritis
NCT06586281 · University of California, San Diego
2025-06-01 – 2027-12-01 · Psoriatic Arthritis
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Crohn's Disease
NCT07577843 · Janssen Research & Development, LLC
2026-05-22 – 2030-07-12 · Crohn Disease
What this study did
Psoriasis
NCT07511647 · Qilu Pharmaceutical Co., Ltd.
2026-05-27 – 2028-02-28 · Plaque Psoriasis
What this study did
Ulcerative Colitis
NCT07577856 · Janssen Research & Development, LLC
2026-05-23 – 2030-10-16 · Colitis, Ulcerative
What this study did
Phase 4 (1)
Psoriasis
NCT04533737 · LEO Pharma
2020-12-17 – 2022-12-07 · Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Psoriatic Arthritis
NCT05071664 · Janssen Research & Development, LLC
2021-10-25 – 2024-08-06 · Arthritis, Psoriatic
What this study did
Early phase / not applicable (1)
Psoriasis
NCT05503875 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-01-01 – 2027-12-31 · Immunoclassification, Psoriasis
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Crohn's Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Guselkumab (Tremfya): this drugApprovedMonoclonal antibodyIL-23 p19Reliable signal
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg)
NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol).
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)ApprovedSmall moleculeGlucocorticoid receptorWeak signalFeatured results are safety only in this race
Budesonide (Ortikos)
ApprovedUS marketing discontinued
—Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signal
NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed
NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34)
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine)
NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab)
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinPartial signal
NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1))
NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1))
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD)
NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w)
NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg))
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinPartial signal
NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed
AfimkibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 3Cell therapyAllogeneic MSC therapyPartial signalNo reviewed efficacy summary in this indication
TH-SC01Phase 3Cell therapyMesenchymal stem cells (MSC)Weak signalNo reviewed efficacy summary in this indication
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 2/3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorPartial signal
NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed
AVB-114Phase 2Cell therapyImplantable cell/biomaterial constructPartial signal
NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29).
AZD7798Phase 2Monoclonal antibodyCCR9Weak signalFeatured results are safety only in this race
ExoFloPhase 2Cell therapyMSC-derived exosomesWeak signalFeatured results are safety only in this race
Golimumab (Simponi)Phase 2Monoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 2Small moleculemiR-124not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinnot yet gradedNo reviewed efficacy summary in this indication
EcoActivePhase 1/2Microbiome therapeuticBacteriophage (anti-AIEC)not yet gradedNo reviewed efficacy summary in this indication
Furestem-CDPhase 1/2Cell therapyAllogeneic MSC therapyWeak signalNo reviewed efficacy summary in this indication
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ALLO-ASCPhase 1Cell therapyAdipose-derived MSC therapyWeak signalNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Hemay007Phase 1Small moleculeTNF-alphaWeak signalNo reviewed efficacy summary in this indication
HRS-7085Phase 1Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
IPG11406Phase 1Small moleculeEBI2Weak signalFeatured results are safety only in this race
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 1Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication
TQH3906Phase 1Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 64 furthest-along competitors are listed; 7 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

6 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tremfya (guselkumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 2Hailey Hailey DiseaseRecruiting
Est. primary completion 2026-12 · NCT06651489 · CT.gov ↗
What to watch
Phase 4PsoriasisRecruiting
Est. primary completion 2026-12-31 · NCT05004727 · CT.gov ↗
What to watch
2027 (12)
January 2027 (1)
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
February 2027 (1)
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-02-10 · NCT06260163 · CT.gov ↗
What to watch
March 2027 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2027-03-25 · NCT05347095 · CT.gov ↗
What to watch
April 2027 (1)
Phase 4Psoriatic ArthritisActive not recruiting
Est. primary completion 2027-04-01 · NCT04929210 · CT.gov ↗
What to watch
June 2027 (2)
Phase 4Psoriatic ArthritisRecruiting
Est. primary completion 2027-06-05 · NCT07141004 · CT.gov ↗
What to watch
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2027-06-08 · NCT06408935 · CT.gov ↗
What to watch
July 2027 (1)
Early phase / not applicablePsoriasisRecruiting
Est. primary completion 2027-07-10 · NCT07532486 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin UlcerActive not recruiting
Est. primary completion 2027-08-13 · NCT06563323 · CT.gov ↗
What to watch
Phase 4PsoriasisRecruiting
Est. primary completion 2027-08-31 · NCT07654751 · CT.gov ↗
What to watch
September 2027 (2)
Early phase / not applicablePsoriatic ArthritisRecruiting
Est. primary completion 2027-09-01 · NCT06586281 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-09-15 · NCT07310095 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-10-27 · NCT05923073 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
March 2028 (1)
Phase 4PsoriasisRecruiting
Est. primary completion 2028-03-01 · NCT06398106 · CT.gov ↗
What to watch
May 2028 (1)
Phase 4PouchitisRecruiting
Est. primary completion 2028-05-30 · NCT06916390 · CT.gov ↗
What to watch
June 2028 (1)
Phase 4PsoriasisRecruiting
Est. primary completion 2028-06-30 · NCT05858632 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2028-11-15 · NCT07499232 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2029-03-15 · NCT07616687 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 3Psoriatic ArthritisRecruiting
Est. primary completion 2031-12-12 · NCT06663332 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 May 2026ApprovalFDA approves TREMFYA label expansion for inhibition of structural joint damage in PsA
US, FDA · Source ↗
19 December 2025ApprovalEC approves Tremfya for paediatric plaque psoriasis
EU, EC · Source ↗
17 November 2025Filing submittedsBLA submitted for structural damage inhibition label in PsA
US, FDA · Source ↗
19 September 2025ApprovalFDA approves TREMFYA subcutaneous induction for ulcerative colitis
US, FDA · Source ↗
20 March 2025ApprovalFDA approves TREMFYA for Crohn's disease
US, FDA · Source ↗
2 December 2024Filing submittedsBLA submitted for pediatric plaque psoriasis
US, FDA · Source ↗
22 November 2024Filing submittedsBLA submitted for TREMFYA SC induction in ulcerative colitis
US, FDA · Source ↗
22 November 2024Topline resultPhase 3 ASTRO study met primary endpoint